Navigation Links
Intellikine Appoints William Rohn to its Board of Directors

LA JOLLA, Calif., Feb. 23 /PRNewswire/ -- Intellikine, Inc., a leader in the development of drugs against the PI3K/mTOR pathway, today announced that William R. Rohn has joined the company's board of directors.

Mr. Rohn has over 30 years of management experience in the biotechnology and pharmaceutical industry, including more than 10 years in executive management positions at IDEC Pharmaceuticals and Biogen Idec, where he served as Chief Operating Officer until his retirement in 2005.  He joined IDEC in 1993 as Senior Vice President, Commercial and Corporate Development, was appointed Senior Vice President, Commercial Operations and was promoted to Chief Operating Officer in 1998. In 2002, he became President, responsible for Sales, Marketing, Business Development, Manufacturing, Quality, Medical Affairs and CMC Regulatory Affairs.  He was responsible for building IDEC's commercial infrastructure to support the launch of Rituxan, the first monoclonal antibody approved in the U.S. for the treatment of cancer.  Mr. Rohn serves on the boards of directors of Elan Corporation, plc, Cerus Corporation, and Cebix, Inc.

"We are delighted to welcome Bill Rohn to Intellikine's board of directors," said Troy Wilson, Ph.D., J.D., President and CEO of Intellikine.  "His strategic insights and experience in growing biotechnology companies, including his experience transitioning IDEC from a development stage company to a very successful commercial enterprise, will be invaluable to Intellikine as we seek to advance our growing pipeline of drugs against the PI3K/mTOR pathway."

"Intellikine has rapidly built one of the best pipelines against the PI3K/mTOR pathway," said William Rohn.  "I am excited about the opportunity to work with the management team and board to build the company and, in particular, to forge industry-leading partnerships to develop and commercialize the company's products for the treatment of cancer, inflammation and other serious diseases."

About Intellikine

Intellikine is a private, clinical-stage company focused on the discovery and development of innovative small molecule drugs targeting the PI3K/mTOR pathway.  Intellikine recently announced the start of a Phase I trial for INK128, a selective TORC1/2 inhibitor for oncology and is advancing INK1197, a PI3K-delta/gamma dual-selective inhibitor for the treatment of inflammatory and respiratory diseases.  Other programs include PI3K-delta/gamma dual-selective inhibitors for oncology, PI3K-alpha/beta selective inhibitors for oncology, as well as other isoform-selective inhibitors. Intellikine has raised $41 million from an outstanding group of life science investors including Abingworth, Sofinnova Ventures, CMEA Capital, Novartis Venture Funds, U.S. Venture Partners, Biogen Idec and FinTech Global Capital.  In addition, Intellikine has a commitment, subject to fulfillment of certain conditions, for another $22.5 million in equity financing from its current investors.  For more information, please visit the company's website at

SOURCE Intellikine, Inc.

Back to top



SOURCE Intellikine, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Aton Pharma Appoints Dr. Wayne Mulcahy to Vice President, Clinical Operations
2. TechTeam Global Appoints Life Sciences Services Director
3. ADVENTRX Appoints Icahn Representative to Board of Directors
4. MS&L Appoints Patricia Archambault as Vice President, Healthcare in Montreal
5. Encorium Re-Appoints Dr. Kai Lindevall as Chief Executive Officer and Appoints Current Director, Shahab Fatheazam, Chairman of the Board
6. Avantium Appoints Gunnar Staaf as CEO Pharma
7. In Preparation for Commercialization of SVARA(TM), TechniScan Appoints Joe Pepper, PhD to Board of Directors
8. Millstone Medical Outsourcing Appoints New Leadership of Memphis Facility
9. Ameritox(R) Appoints Jay B. Zimmerman as Chief Operating Officer
10. Jazz Pharmaceuticals Appoints Kathryn Falberg as Chief Financial Officer
11. Patient Safety Technologies, Inc. Appoints Marc L. Rose, CPA (PA), Chief Financial Officer
Post Your Comments:
(Date:12/1/2015)... , Dec. 1, 2015  Athletic apparel ... founder have agreed to pay $1.35 million to ... advertised the company,s copper-infused compression clothing would relieve ... arthritis and other diseases. Tommie ... requires the company and its founder and chairman ...
(Date:12/1/2015)... 2015 Pharma Tech Outlook recently conducted a ... Data Management Solution Providers - 2015 .  After careful ... CEOs, CIOs, VCs, analysts, and the Pharma Tech Outlook ... top 10 clinical data management solution providers (check out ... and 36 respectively). --> ...
(Date:12/1/2015)... and PITTSBURGH , Dec. ... announced that it expects to be the first to ... funded by international donors, TLE400 (Tenofovir Disoproxyl Fumarate 300 ... for $99 per patient, per year. Mylan partnered with ... The significantly reduced price could generate savings of tens ...
Breaking Medicine Technology:
(Date:12/1/2015)... CA (PRWEB) , ... December 01, 2015 , ... ... States, today announced that its iconic bottle has won top honors in Beverage World ... The Company also announced that it has been selected as a 2015 U.S.A. ...
(Date:12/1/2015)... Houston, TX (PRWEB) , ... December 01, 2015 , ... ... owner of Vitenas Cosmetic Surgery, has been named by MedEsthetics magazine as the Best ... best of the best among the many elite aesthetic physicians honored by the industry ...
(Date:12/1/2015)... ... 01, 2015 , ... Speech and physical therapies are traditionally ... technologies and under the right circumstances, these practices can be merged. This ... to his or her therapeutic sessions, as well as gives the physical and ...
(Date:12/1/2015)... ... December 01, 2015 , ... Growth in medical payments per ... decreases in utilization of hospital and nonhospital care, according to a recent study by ... for Louisiana, 16th Edition , found medical payments per claim with more than seven ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... identification tests to continue the expansion of the company’s growing product line of ... for Chinook (Oncorhynchus tshawytscha) and Sockeye (Oncorhynchus nerka) – allow InstantLabs to offer ...
Breaking Medicine News(10 mins):